PEGPH20

Phase 2Small molecule

HHalozyme Therapeutics

PEGPH20 is one of 155 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

154

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Pancreatic CancerActive, not recruiting

CholangiocarcinomaActive, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 2

Active, not recruiting

Pancreatic AdenocarcinomaPreclinical

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

CholangiocarcinomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Preclinical

108 2

PEGPH20

HHalozyme Therapeutics

Phase 2

3 3

Byetta

AstraZeneca

Preclinical

1 4

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 5

Sulfonylureas

Eli Lilly

Preclinical

1 6

Thiazolidinediones

Sanofi

Preclinical

1 7

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 8

Meglitinides

Sanofi

Preclinical

1 9

Active Comparator

Moderna

Preclinical

1 10

Secretin-Ferring

Ferring

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/AActive, not recruiting

Pancreatic Adenocarcinoma

NCT02921022

Clinical

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma3 trials

Study Evaluating NEOadjuvant Immunotherapy in Resectable PANCreatic Ductal Adenocarcinoma

Terminated·GGulam Manji·Phase 2·NCT03979066·1 enrolled

PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma

Terminated·AAndrew Ko·Phase 2·NCT02487277·3 enrolled

A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Completed· Roche logo

Roche·Phase 1/2·NCT03193190·341 enrolled

Pancreatic Cancer3 trials

Study of Gemcitabine + PEGPH20 vs Gemcitabine Alone in Stage IV Previously Untreated Pancreatic Cancer

Completed·HHalozyme Therapeutics·Phase 1/2·NCT01453153·28 enrolled

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

Completed·SSWOG Cancer Research Network·Phase 1/2·NCT01959139·126 enrolled

PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer

Completed·HHalozyme Therapeutics·Phase 2·NCT01839487·279 enrolled

Patients With Advanced Solid Tumors2 trials

Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors

Completed·HHalozyme Therapeutics·Phase 1·NCT01170897·27 enrolled

Safety Study of PEGPH20 Given to Patients With Advanced Solid Tumors

Completed·HHalozyme Therapeutics·Phase 1·NCT00834704·14 enrolled

Pancreatic Adenocarcinoma2 trials

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

Completed·MMemorial Sloan Kettering Cancer Center·N/A·NCT02241187·2 enrolled

Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Active, not recruiting·MMemorial Sloan Kettering Cancer Center·N/A·NCT02921022·110 enrolled

Pembrolizumab1 trial

A Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) With Pembrolizumab in Participants With Selected Hyaluronan High Solid Tumors

Completed·HHalozyme Therapeutics·Phase 1·NCT02563548·56 enrolled

2 more indications

Metastatic PDAC1 trial

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Unknown status·PPancreatic Cancer Research Team·Phase 2·NCT03634332·35 enrolled

Cholangiocarcinoma1 trial

Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; and CIS and GEM Alone in Participants With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma

Terminated·HHalozyme Therapeutics·Phase 1·NCT03267940·85 enrolled

Sources

References

[1]
ClinicalTrials.gov — 13 trial records for PEGPH20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PEGPH20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PEGPH20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Halozyme Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHalozyme Therapeutics

PEGPH20

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma3 trials

Pancreatic Cancer3 trials

Patients With Advanced Solid Tumors2 trials

Pancreatic Adenocarcinoma2 trials

Pembrolizumab1 trial

Metastatic PDAC1 trial

Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News